Australia Hemato Oncology Testing Market Size & Outlook

The hemato oncology testing market in Australia is expected to reach a projected revenue of US$ 109.7 million by 2028. A compound annual growth rate of 12.7% is expected of Australia hemato oncology testing market from 2021 to 2028.
Revenue, 2020 (US$M)
$42.0
Forecast, 2028 (US$M)
$109.7
CAGR, 2021 - 2028
12.8%
Report Coverage
Australia

Australia hemato oncology testing market highlights

  • The Australia hemato oncology testing market generated a revenue of USD 42.0 million in 2020 and is expected to reach USD 109.7 million by 2028.
  • The Australia market is expected to grow at a CAGR of 12.7% from 2021 to 2028.
  • In terms of segment, lymphoma was the largest revenue generating cancer type in 2020.
  • Lymphoma is the most lucrative cancer type segment registering the fastest growth during the forecast period.


Hemato oncology testing market data book summary

Market revenue in 2020USD 42.0 million
Market revenue in 2028USD 109.7 million
Growth rate12.7% (CAGR from 2020 to 2028)
Largest segmentLymphoma
Fastest growing segmentLymphoma
Historical data2018 - 2019
Base year2020
Forecast period2021 - 2028
Quantitative unitsRevenue in USD million
Market segmentationLeukemia, Lymphoma, MPNs, Other Cancers
Key market players worldwideRoche Holding AG, Abbott Laboratories, Qiagen NV, Danaher Corp, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Illumina Inc, Bio-Techne Corp


Other key industry trends

  • In terms of revenue, Australia accounted for 1.8% of the global hemato oncology testing market in 2020.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2028.
  • In Asia Pacific, Japan hemato oncology testing market is projected to lead the regional market in terms of revenue in 2028.
  • India is the fastest growing regional market in Asia Pacific and is projected to reach USD 188.8 million by 2028.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Hemato Oncology Testing Market Companies

Name Profile # Employees HQ Website

Australia hemato oncology testing market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemato oncology testing market will help companies and investors design strategic landscapes.


Lymphoma was the largest segment with a revenue share of 46.19% in 2020. Horizon Databook has segmented the Australia hemato oncology testing market based on leukemia, lymphoma, mpns, other cancers covering the revenue growth of each sub-segment from 2018 to 2028.


Increasing government initiatives to improve diagnosis rate of blood cancer in the region is anticipated to significantly support the market growth over the forecast period. For instance, in September 2019, the Australian Government announced to establish a National Action Plan to improve diagnosis and treatment of blood cancers in the region.

In February 2019, the Federal Government of Australia granted USD 1.3 million in funds to establish a multi-disciplinary blood cancer clinic to screen families at risk of lymphoma and leukemia. In addition, as part of 2020/2021 Budget, the Morrison Government has planned to offer more than USD 600,000 to the Foundation of Leukaemia as a part of the country’s first National Strategic Plan for Blood Cancer.

Moreover, blood cancers, comprising lymphoma, leukemia, and myeloma are projected to account for more than 1 in 10 cancer demises in Australia in 2020. Furthermore, the number of blood cancers identified each year is increasing; from around 12,500 cases in 2010 to 17,300 in 2020 and it is projected that there will be around 5,600 deaths from blood cancer in 2020.

Reasons to subscribe to Australia hemato oncology testing market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Australia hemato oncology testing market databook

  • Our clientele includes a mix of hemato oncology testing market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Australia hemato oncology testing market , including forecasts for subscribers. This country databook contains high-level insights into Australia hemato oncology testing market from 2018 to 2028, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Australia hemato oncology testing market size, by cancer type, 2018-2028 (US$M)

Australia Hemato Oncology Testing Market Outlook Share, 2020 & 2028 (US$M)

Australia hemato oncology testing market size, by cancer type, 2018-2028 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more